{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-117228","form_type":"8-K","ticker":"HYPD","cik":"0001682639","company_name":"HYPERION DEFI, INC.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.052005+00:00","generated_at":"2026-06-08T05:15:42.913615+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Eyenovia Q3 net loss $7.3M; acquired US rights to APP13007; appointed new director","bullets":["Net loss of ~$7.3M ($0.18 EPS) in Q3 2023, vs ~$7.3M loss ($0.21 EPS) in Q3 2022.","Cash & equivalents $20.7M at Sept 30, 2023, down from $22.9M at Dec 31, 2022.","Acquired US commercial rights to APP13007 (post-surgical ocular pain/inflammation); PDUFA date March 4, 2024.","FDA approved Coastline International as Mydcombi contract manufacturer; national launch planned early 2024.","Michael Geltzeiler appointed as independent director and Audit Committee chair, effective Nov 14, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-117228","json":"https://secwatch.observer/filing/0001104659-23-117228.json","markdown":"https://secwatch.observer/filing/0001104659-23-117228.md","text":"https://secwatch.observer/filing/0001104659-23-117228.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682639/000110465923117228/0001104659-23-117228-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682639/000110465923117228/tm2330550d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:15:42.913615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3a9396aa760e55711364bb4f643afaf27c3eb577","claim":"HYPERION DEFI, INC. reported the third quarter ended September 30, 2023 results: net income approximately $(7.3) million, EPS $(0.18) per share.","evidence_excerpt":"For the third quarter of 2023, net loss was approximately $(7.3) million, or $(0.18) per share compared to a net loss of approximately $(7.3) million, or $(0.21) per share, for the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1682639/000110465923117228/0001104659-23-117228-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"approximately $(7.3) million"},{"label":"EPS","value":"$(0.18) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"618c91f259","claim":"Michael Geltzeiler was appointed as Director and Chair of Audit Committee at HYPERION DEFI, INC..","evidence_excerpt":"On November 10, 2023, the Board of Directors (the “Board”) of the Company appointed Michael Geltzeiler to serve on the Board and as the Chair of the Audit Committee of the Board (the “Audit Committee”), in each case, effective November 14, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1682639/000110465923117228/0001104659-23-117228-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director and Chair of Audit Committee"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}